

# 日本での皮膚感作性代替法開発状況 について

Update on *in vitro* skin sensitization  
assay in Japan



Hajime Kojima,  
JaCVAM, NIHS

# Contents

1. ICATM cooperation


2. IL-8 Luc assay

3. AOP and IATA



# ICATM Flam work

ICATM is a **voluntary** international cooperation of national organizations: Canada, the European Union, Japan, South Korea, and the United States.



# Acute Contact Dermatitis Test Methods 1

Method	Current status	Lead Organization	International acceptance
Murine Local lymph Node Assay (LLNA)	Completed		OECD TG 429 (2002), ISO (2002)
Updated LLNA	Completed		Updated OECD TG 429 (2010), ISO (2010)
Reduced LLNA (rLLNA)	Completed		Updated OECD TG 429 (2010)
LLNA:DA	Completed		OECD TG442A (2010)
LLNA:BrdU-ELISA	Completed		OECD TG 442B (2010)
Harminized performance standard for the LLNA	Completed		Updated OECD TG 429 (2010)


# Acute Contact Dermatitis Test Methods 2


Method	Current status	Lead Organization	International acceptance
Nonradioactive LLNA protocol (LLNA: BrdU-Flow Cytometry)	<ul style="list-style-type: none"> <li>- ICCVAM international peer review, 2009</li> <li>- Recommendations pending a review of lead laboratory data and inter-laboratory study.</li> </ul> KoCVAM validation study planned	NICEATM-ICCVAM, KoCVAM	
<i>In vitro</i> skin sensitization assays (h-CLAT; DPRA; MUSST)	Multi-laboratory validation ends in August 2012 (h-CLAT and MUSST). DPRA peer review is ongoing.	EURL ECVAM; JaCVAM and NICEATM-ICCVAM VMT liaison members	Proposal for an Adverse Outcome Pathway for skin sensitization has been approved by the OECD. SPSFs approved for the DPRA, Keratinosens and h-CLAT.
<i>In vitro</i> skin sensitization assay KeratinoSens	External Validation Study, peer review ongoing	EURL ECVAM	SPSF approved
<i>In vitro</i> skin sensitization assay IL-8 Luc assay	METI-sponsored validation study ongoing	JaCVAM; EURL ECVAM, NICEATM-ICCVAM, KoCVAM and Health Canada VMT liaisons	

# JaCVAM correlated International validation studies for skin sensitization assay


1. LLNA:DA
2. LLNA:BrdU-ELISA
3. h-CLAT assay (with ECVAM)
4. IL-8 reporter gene assay (with ICATM)

# IL-8 reporter gene assay (IL-8 Luc assay)








**HTP assay for carcinogenicity** (Hatano Research Institute, Food & Drug Safety Center)



**HTP assay for immunotoxicity** (Tohoku University)



**HTP assay for developmental toxicity** (Sumitomo Chemical Co., Ltd.)





**Brush up on basic technology and support**

1) Multicolor luciferase reporter assay (National Institute of Advanced Industrial Science & Technology and Toyobo Co., Ltd.)

2) Human artificial chromosome (HAC) vector method (Tottori University)

## Example of toxicity test for immunology using a multireporter assay

Generation of T cells stably express SLG, SLO and SLR enzymes under two marker gene promoters and internal control gene promoter.



Cells display stable luciferase expressions and respond to chemicals during prolonged culture.

Chemical risk analysis  
in a 96well plate  
format HTP assay

Reaction with Tripluc<sup>®</sup> assay Reagents



## Main members for IL-8 Luc assay Validation Management Team

Name	Role and expertise	Affiliation
<b>Trial Coordinator Noriho Tanaka</b>	VMT Chairperson,	HRI and OTIP, Japan
<b>Lead Lab Yutaka Kimura* Setsuya Aiba**</b>	*VMT Co-chair **Developer of this assay Test method, expertise underlying science	Tohoku Univ., Japan
<b>Hajime Kojima</b>	Management of quality control	JaCVAM, NIHS, Japan (JaCVAM representative)
<b>Takashi Omori</b>	Data analysis, biostatistics dossier	Doshisha Univ., Japan
<b>Liaison members</b>		
<b>ECVAM liaison Emanuela Corcini</b>	Test system expertise, multi-study validation expertise, immunotoxicity expertise	Mila Univ., Italy
<b>ICCVAM liaison Warren Casey</b>	Test system expertise, multi-study validation expertise	NICEATM, USA
<b>KoCVAM liaison Ai-Young Lee</b>	Test system expertise, multi-study validation expertise	KoCVAM, Korea

# Stages of IL-8 Luc assay validation study under Modular approach

Module 2: Within-lab Reproducibility (5 coded)

Module 3: Transferability

Phase 0 (*finished*) 10 non-coded

Module 4: Between-Lab Reproducibility


Phase I 20 coded

Module 5: Predictive capacity

Phase II ?? coded

Present  
time

# AOP and IATA







Figure 3. Flow diagram of the pathways associated with skin sensitisation.

# OECD strategy for Regulatory acceptance




AOP: Adverse  
Outcome Pathway


TG: Test Guideline

A guidance document on the  
Evaluation and Application of  
Integrated Approaches to Testing  
and Assessment (IATA)


# Adverse Outcome Pathways on skin sensitization assay



**Figure 3:** Timeline for implementation of EU legislation and skin sensitisation information requirements.



**Figure 1:** EURL ECVAM roadmap for achieving skin sensitisation hazard identification and classification based on alternative methods.





About JaCVAM

Update on JaCVAM

Academic activities

Submission of Alternative Methods

International Cooperation

# Thank you for your attention

**Policy and Mission:** JaCVAM's policy and mission is to promote the 3Rs in animal experiments for the evaluation of chemical substance safety in Japan and establish guidelines for new alternative experimental methods through international collaboration.

the 3Rs in animal experiments—Reduction (of animal use)

Refinement (to lessen pain or distress and to enhance animal well-being)

Replacement (of an animal test with one that uses non-animal systems or phylo-genetically lower species)  
(OECD GD34)

## News

- 📧 **[NEW]** news texts dummy texts news texts dummy texts  
news texts dummy texts(2009.7.16)
- 📧 news texts dummy texts news texts (2009.7.3)
- 📧 news texts dummy texts news texts dummy texts news  
texts dummy texts (2009.7.3)

## Contents

- 📧 About JaCVAM
  - Message from JaCVAM / Policy and Mission of JaCVAM /
  - Organization of JaCVAM / Glossary /
  - Proposal for Engagement Rules
- 📧 JaCVAM Activities